electroCore to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
electroCore (ECOR) will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 11, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
electroCore (ECOR) will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 11, 2026. The event will take place at The Westin New York Grand Central in New York City. Joshua Lev, Co-Chief Executive Officer, President and Chief Financial Officer, will present and host one-on-one investor meetings throughout the day.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKAWAY, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, taking place on Wednesday, November 11, 2026, at The Westin New York Grand Central in New York City.
Joshua Lev, Co-Chief Executive Officer, President and Chief Financial Officer, will present at the conference and host one-on-one meetings with investors throughout the day.
Investors interested in scheduling a one-on-one meeting should contact their Canaccord Genuity sales representative.
About electroCore, Inc.
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
